Saliva test could personalize care for Opioid-Affected newborns

NCT ID NCT05937594

Recruiting now Knowledge-focused Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at tiny molecules called microRNAs in the saliva of newborns exposed to opioids before birth. Researchers want to see if these molecules can predict how severe withdrawal symptoms will be and guide treatment. The goal is to move away from one-size-fits-all care and toward personalized medicine for babies with neonatal abstinence syndrome. Fifty infants will be enrolled to measure microRNA levels and track their development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple saliva test to help doctors tailor treatment for each baby with opioid withdrawal, potentially reducing hospital stays and improving development.
What could go wrong: This is a small, early-stage study focused on finding biomarkers, not testing a treatment. The results may not lead to immediate changes in care or apply to all babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL ABSTINENCE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neonatal abstinence syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEONATAL ABSTINENCE SYNDROME NEONATAL OPIOID WITHDRAWAL SYNDROME

Contacts and locations

Locations

Penn State Milton S. Hershey Medical Center
RECRUITING

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.